LEAD PLAINTIFF DEADLINE IS DECEMBER 26, 2025.
If you have suffered losses and would like to discuss your rights, please fill out this form or you may contact Jonathan Naji, Esq. at (484) 270-1453 or via e-mail at info@ktmc.com.
Case Background:
Class action lawsuits have been filed on behalf of those who purchased or otherwise acquired DexCom, Inc. ("Dexcom") (NASDAQ: DXCM) common stock between January 8, 2024, and September 17, 2025, inclusive (the “Class Period”).
DexCom is a medical device company primarily focused on the design, development, and commercialization of continuous glucose monitoring (“CGM”) systems for the management of diabetes and metabolic health. DexCom’s products include, among others, the G6 and G7 CGM systems, which DexCom launched in 2018 and 2023, respectively. The G7 is DexCom’s flagship product and, accordingly, its commercial success is of paramount importance to both investors and DexCom.
The Class Period begins on January 8, 2024, when Defendant Sayer presented at the JPMorgan Healthcare Conference. During this presentation, Defendant Sayer provided Dexcom’s initial financial outlook for fiscal year 2024 and commented that “[y]ou can’t achieve results like this, though, without having a great platform, and that’s what our G7 is.” He continued that “for G7, that great science starts with this accuracy. This is the most accurate sensor on the market today and the most accurate sensor that’s ever been produced by us.”
The truth began to emerge, on July 25, 2024, when after the market closed, DexCom hosted a conference call with investors and analysts to discuss its financial results for the second quarter of 2024. During the call, DexCom touted the company’s purported enhancements to the G7. Likewise, during the same call, DexCom touted the company’s enhancements to the G7, as well as it’s ramping up of the G7’s manufacturing facilities.
On March 7, 2025, DexCom disclosed in an SEC filing that, three days earlier, the company had received a warning letter (the “Warning Letter”) from the FDA related to concerns about manufacturing processes and quality management systems at certain of DexCom’s facilities. On this news, DexCom’s stock price fell $7.12 per share, or 9.15%, to close at $70.72 per share on March 10, 2025, the next trading day.
On March 25, 2025, the FDA published the Warning Letter on its website, revealing that DexCom had “adulterated” its G6 and G7 products by “modif[ying] the G6 and G7 sensors” without prior regulatory approval, thereby subjecting the devices to “larger inaccuracies” that “cause higher risks for users who rely on the sensors to dose insulin or make other diabetes treatment decisions.” On this news, DexCom’s stock price fell $3.19 per share, or 4.24%, over the following two trading sessions, to close at $72.13 per share on March 26, 2025.
On September 8, 2025, equity research firm Oppenheimer issued a note downgrading DexCom’s rating to “perform” from “outperform.” Oppenheimer also removed its $102.00 price target on DexCom’s stock. Oppenheimer cited, among other things, patient concern with the G7’s poor accuracy, failed sensor insertions, abrupt stoppages, and other issues, noting that “field checks point to rising concerns about G7 accuracy/performance.” On this news, DexCom’s stock price fell $2.51 per share, or 3.12%, to close at $78.00 per share on September 8, 2025.
Then, on September 18, 2025, Hunterbrook published a report addressing DexCom, entitled “Dexcom’s Fatal Flaws”. The Hunterbrook report revealed, among other things, that issues and health risks posed by adulterated G7 devices were more severe and widespread than previously disclosed, citing FDA documents it had procured via a Freedom of Information Act request, as well as various comments from doctors, patients and their families, and former DexCom employees. Specifically, the Hunterbrook report found that “G7 users have been hospitalized and died” following inaccurate glucose readings, linking these deadly incidents to adulterated G7 devices and DexCom’s willingness to cut corners to meet margins. On this news, DexCom’s stock price fell $8.99 per share, or 11.76%, over the following two trading sessions, to close at $67.45 per share on September 19, 2025.
The complaints allege that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) DexCom had made material design changes to its G6 and G7 CGM systems that were unauthorized by the FDA; (2) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (3) DexCom’s purported enhancements to the G7, as well as the device’s reliability, accuracy, and functionality, were overstated; (4) DexCom downplayed the true scope and severity of the issues and health risks posed by adulterated G7 devices; (5) all the foregoing subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action, as well as significant legal, reputational, and financial harm; and (6) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.
What is a Lead Plaintiff?
A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.